The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MYC+ relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.
 
Narendranath Epperla
No Relationships to Disclose
 
Kami J. Maddocks
Honoraria - Bristol-Myers Squibb; Janssen; Pharmacyclics; Seagen
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen; Pharmacyclics; Seagen
Research Funding - Merck; Pharmacyclics
 
Mohamed Salhab
No Relationships to Disclose
 
Julio C. Chavez
Consulting or Advisory Role - Incyte
Speakers' Bureau - Abbvie; Janssen
 
Nishitha M. Reddy
Consulting or Advisory Role - Abbvie; Celgene; Gilead Sciences; Infinity Pharmaceuticals
 
Reem Karmali
Speakers' Bureau - Celgene
 
Elvira Umyarova
No Relationships to Disclose
 
Veronika Bachanova
Honoraria - Seagen
Consulting or Advisory Role - Juno Therapeutics; Sunesis Pharmaceuticals; Zymeworks
Research Funding - Oxis International (Inst)
 
Martha Jane Glenn
No Relationships to Disclose
 
Ana Carolina Xavier
No Relationships to Disclose
 
Zheng Zhou
No Relationships to Disclose
 
Francisco J. Hernandez-Ilizaliturri
No Relationships to Disclose
 
Stefan K. Barta
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - Celgene; Janssen
Research Funding - Celgene; Merck; Seagen
 
Frederick Lansigan
Consulting or Advisory Role - Celgene; Pharmacyclics; Spectrum Pharmaceuticals
Research Funding - Spectrum Pharmaceuticals; Teva
 
Amitkumar N. Mehta
No Relationships to Disclose
 
Christopher Flowers
Consulting or Advisory Role - Bayer; Gilead Sciences; OptumRx; Seagen
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immune Design (Inst); Infinity Pharmaceuticals (Inst); Janssen Oncology (Inst); Onyx (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Genentech/Roche; Gilead Sciences
 
Jonathon Brett Cohen
Consulting or Advisory Role - Abbvie; Celgene; Infinity Pharmaceuticals; Millennium; Novartis; Pharmacyclics; Seagen
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Takeda
 
Timothy S Fenske
Consulting or Advisory Role - Celgene; Pharmacyclics; Seagen
Research Funding - Millennium
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - Celerant; Janssen Oncology; MedImmune
Speakers' Bureau - Sanofi
Research Funding - Spectrum Pharmaceuticals; Takeda
 
Luciano J Costa
Honoraria - Sanofi
Research Funding - Sanofi